

GENESIS FERTILITY CENTER PUBLIC COMPANY LIMITED

MANAGEMENT DISCUSSION AND ANALYSIS FOR THE QUARTER 2

ENDED
30 JUNE 2026

GENESIS FERTILITY CENTER

PUBLIC COMPANY LIMITED

บริษัท เจเนซิส เฟอริลิตี เซ็นเตอร์ จำกัด (มหาชน)



GFC Ubon
(Northeastern)



GFC Rama 9
International
(Bangkok)



GFC Rama 3
(Bangkok)



"Excellent" Rating in Thai Investors Association
for the Second Consecutive Year



5-Star Rating "Excellent" for 2025 in Thai Institute
of Directors for the Second Consecutive Year

ESG100
EMERGING

Environmental, Social, and Governance

Named to the ESG100 list for the first time in 2024.

ESG100
Environmental Social Governance 2025

Recognized as a listed company demonstrating outstanding
performance in Environmental, Social,
and Governance (ESG) practices.



GFC Your Success, Our Commitment



Executive Summary

For the Three-Month and Six-Month Periods Ended June 30, 2026

Operating Performance Overview

In Q2/2026, Genesis Fertility Center Public Company Limited and its subsidiaries (the “Group”) reported revenue from services of Baht 58.33 million, a decrease of Baht 31.31 million or 34.93 percent compared with the same period of the previous year, and a decrease of Baht 8.87 million or 13.20 percent compared with the previous quarter, with a net loss of Baht 5.56 million compared with a net profit of Baht 8.47 million in the same period of the previous year. For the first six months of 2026, the Group recorded revenue from services of Baht 125.54 million, a decrease of 30.30 percent, and a net loss of Baht 9.92 million compared with a net profit of Baht 15.40 million in the same period of the previous year.

The operating results for the first six months of 2026 include one-time expenses totaling Baht 3.60 million, comprising the write-off of assets arising from an exchange-of-services contract, employee severance payments together with related legal professional fees, and a provision for expired inventories awaiting destruction. Excluding these items, the loss before income tax from normal operations for the six-month period would be Baht 8.67 million, compared with the reported loss of Baht 12.27 million.

The softer operating performance reflects a slowdown in service volume in line with domestic economic conditions and purchasing power, during a period in which the Group is undergoing a strategic transition toward expanding its international customer base and fully utilizing the capacity of the GFC Rama 9 International branch. Service volume reached its lowest monthly level in May 2026 and began to improve in June 2026. Nevertheless, the Group continues to maintain a strong financial position, remains free of borrowings from financial institutions, and continues to advance its long-term strategic plan.

Revenue Analysis

Revenue from ICSI services, the core service line accounting for 63.99 percent of total revenue, declined from Baht 62.92 million to Baht 37.42 million, in line with the number of treatment cycles (OPU), which decreased from 216 cycles to 127 cycles, or 41.20 percent compared with the same period of the previous year (266 cycles for the six-month period compared with 432 cycles, a decrease of 38.43 percent). This also affected revenue from Preimplantation Genetic Testing for Aneuploidies (PGT-A), a related downstream service, which declined by 43.66 percent. Meanwhile, average revenue per treatment cycle increased by 10.67 percent to Baht 0.46 million per cycle, reflecting the adjustment of treatment programs, which partially offset the volume impact.

Oocyte freezing and oocyte storage services continued to grow strongly at 41.64 percent compared with the same period of the previous year (36.53 percent growth for the six-month period), in line with global market trends, and remain the service segment the Group plans to drive as a new growth engine. In terms of customer base structure, the Group is progressing with its plan to increase the proportion of foreign customers from 15 percent to 25 percent through its network of nine international agents and overseas marketing activities.

Gross Profit Margin Analysis

Gross profit margin in Q2/2026 was 33.80 percent, down from 41.32 percent in the same period of the previous year and 35.49 percent in the previous quarter, as revenue declined at a faster rate

than the decline in costs, given the high fixed-cost component embedded in cost of services — particularly medical personnel compensation and depreciation. Excluding the one-time provision for expired inventories awaiting destruction of Baht 0.91 million recorded in this quarter, the gross profit margin would be 35.36 percent, close to the previous quarter, indicating that cost efficiency per unit of revenue did not deteriorate further between quarters.

Analysis of Earnings before Depreciation, Amortization, Financial Cost and Income Tax Expenses (EBITDA)

EBITDA in Q2/2026 stood at Baht 0.57 million, a decrease of Baht 22.26 million or 97.52 percent compared with the same period of the previous year, and a decrease of Baht 7.12 million or 92.64 percent compared with the previous quarter, with an EBITDA margin of 0.97 percent. For the six-month period, EBITDA stood at Baht 8.25 million, or 6.57 percent of revenue, a decrease of 81.11 percent from the same period of the previous year.

The decline arose from three key factors: (1) lower revenue from services in line with the number of treatment cycles; (2) the largely fixed nature of cash costs and expenses — particularly employee-related expenses and utilities — which cannot be scaled down as quickly as the decline in revenue; and (3) the one-time expenses recorded in each period. Excluding one-time items, EBITDA from normal operations for the six-month period would be Baht 11.85 million, or 9.44 percent of revenue.

(Detailed analysis is set out in the Management Discussion and Analysis section.)

Financial Position and Liquidity

Although operating performance softened in this period, the Group's financial position remains strong, with details as follows:

- Cash and cash equivalents of Baht 98.28 million.
- Total assets of Baht 620.76 million.
- Debt-to-equity (D/E) ratio of 0.12 times, and free of borrowings from financial institutions.
- Current ratio of 2.76 times.

Net cash provided by operating activities for the six-month period was positive at Baht 2.32 million, while cash decreased by a net Baht 32.47 million, largely reflecting dividend payments to the Company's shareholders and to the non-controlling shareholders of a subsidiary totaling Baht 24.82 million. This strong capital structure continues to form a key foundation supporting the Group's strategic investment plan, the development of strategic partnership networks, and opportunities to consider joint ventures in line with the New S-Curve growth strategy.

Approach to Driving Operating Performance in the Remaining Quarters of the Year

Management recognizes the need to accelerate the recovery of service volume and to restore the absorption of fixed costs to an appropriate level. During the first half of the year, the Group continued to execute the four 2026 Driving Strategies and has strengthened its second-half work plans with clearly defined activities, targets and timelines. Key progress and plans are summarized as follows:

- 1) Core Capacity Utilization** — In Q2, the Group intensified its digital marketing and AI Search Visibility programs to support the recovery of case volume in the second half. Key activities scheduled for the second half include the Company's 9th-anniversary celebration campaign during July–September 2026, oocyte freezing and storage campaigns targeting Gen Z customers through beauty influencers and micro influencers in Q3, the expansion of

WomanHealth screening services, and a patient referral program with physicians of partner hospitals commencing from Q3 onwards.

- 2) **International Client Expansion** — The network of international agents is complete at nine agents as planned, and in June 2026 the Group upgraded its service packages for international agents to be more competitive. In the second half, a health roadshow is scheduled in Shenzhen, the People's Republic of China, in July 2026, which is expected to begin contributing cases from Q3–Q4, together with participation in the MAI Festival and Thailand Wellness events during August–October 2026, in order to raise the proportion of foreign customers from 15 percent toward the target of 25 percent.
- 3) **Ecosystem & Strategic Network Alliances** — Cooperation with more than 10 partner hospitals and clinics under signed agreements is entering the implementation stage in the second half, covering patient referral programs with partner-hospital physicians, laboratory service collaborations, and the shared use of medical personnel, which will enhance the utilization of the Group's existing laboratory capacity and personnel.
- 4) **New S-Curve Activation** — The Group is studying the establishment of an ICSI center with partner hospitals, the expansion of the external (B2B) laboratory customer base, and Polyploidy testing services of the genetic testing business, which will reduce reliance on intragroup volume, as well as preparing to commence the pharmaceutical and medical supplies management business of a subsidiary toward the end of 2026.
- 5) **Cost Management and Financial Discipline** — Alongside revenue recovery, the Group implemented concrete cost measures in the first half, resulting in a year-on-year decrease in overall selling and administrative expenses (excluding one-time items). For the second half, the Group has entered into a lease agreement for a 124.80-kilowatt solar rooftop power system, which will reduce utility costs once installation is complete, and is upgrading its medicine and medical supplies inventory management to align with actual case volumes. The Group will further review its fixed cost structure should revenue volume not recover as planned.

Dividend Payment

In accordance with the resolution of the Annual General Meeting of Shareholders held on April 27, 2026, the Company paid the final dividend from the 2025 operating results at the rate of Baht 0.10 per share, totaling Baht 22.00 million, on May 26, 2026. Subsequently, on August 10, 2026, the Board of Directors' Meeting No. 4/2026 approved the payment of an interim dividend from the Company's retained earnings at the rate of Baht 0.03 per share, totaling Baht 6.60 million, with payment scheduled by September 8, 2026, reflecting the strength of the Company's financial position and its continued care for shareholders in line with the Company's dividend payment policy.

Confidence in Future Direction

Management assesses that the softer operating performance in the first half resulted from domestic purchasing power conditions and the strategic transition period. The recovery in the second half depends on the success of work plans with clearly defined timelines, namely: (1) the recovery of service volume through the 9th-anniversary celebration campaign and proactive marketing activities in Q3; (2) higher capacity utilization of the GFC Rama 9 International branch; (3) case volume from the network of nine international agents following the package upgrade and the Shenzhen roadshow; and (4) the commencement of revenue generation from partnerships with more than 10 hospitals and clinics. Management has established monthly monitoring mechanisms covering case numbers, the conversion rate from consultations to treatment, and revenue per treatment cycle, in order to adjust revenue and cost measures in a timely manner.

Against the backdrop of the global Assisted Reproductive Technology (ART) industry, which continues to grow on structural factors — including declining fertility rates, delayed childbearing, and the growth of fertility tourism, with the oocyte and embryo freezing services market growing at an average rate of more than 16 percent per year between 2025 and 2034 — the Group continues to enjoy significant competitive advantages, including:

- Treatment success rate of 74 percent, and one of the top three leading clinics in Thailand by patient volume.
- Recipient of the Fertility Centre of the Year — Asia-Pacific and Embryologist of the Year — Asia-Pacific awards from GlobalHealth Asia-Pacific.
- A team of embryology scientists certified by ESHRE (European Society of Human Reproduction and Embryology).
- An embryology laboratory built to Class 1,000 cleanroom standards, with Thailand's first cryopreservation storage system.

Management reaffirms its commitment to driving the Group toward its vision of becoming a leading organization in infertility treatment in the ASEAN region, while maintaining financial discipline and good corporate governance in line with ESG standards, in order to deliver sustainable growth for shareholders and all stakeholders.

Operating Results Summary for the Three-Month and Six-Month Periods Ended June 30, 2026

Consolidated Statement of Profit or Loss — for the Three-Month Period

Unit : Million Baht	Q2 2025	Q2 2026	YoY (Baht)	YoY (%)	Q1 2026	QoQ (Baht)	QoQ %
Revenue from services	89.65	58.33	(31.31)	(34.93)	67.21	(8.87)	(13.20)
Cost of services	52.60	38.62	(13.99)	(26.59)	43.35	(4.73)	(10.92)
Gross profit	37.04	19.72	(17.33)	(46.77)	23.86	(4.14)	(17.34)
Other income	0.83	0.13	(0.70)	(84.18)	0.02	0.11	563.02
Distribution costs	6.43	7.06	0.63	9.81	5.87	1.19	20.25
Administrative expenses	20.85	19.31	(1.54)	(7.39)	21.66	(2.35)	(10.85)
Profit (loss) from operating activities	10.59	(6.52)	(17.12)	(161.58)	(3.66)	(2.86)	(78.26)
Financial cost	0.51	0.46	(0.05)	(9.46)	0.51	(0.04)	(8.67)
Expected credit losses	-	-	-	-	1.12	(1.12)	(100.00)
Profit (loss) before income tax expenses	10.08	(6.99)	(17.07)	(169.31)	(5.28)	(1.70)	(32.21)
Income tax expenses	1.61	(1.43)	(3.04)	(188.57)	(0.92)	(0.51)	(55.16)
Net profit (loss) for the year	8.47	(5.56)	(14.03)	(165.64)	(4.36)	(1.19)	(27.37)
Attributable to Parent Company	7.06	(6.82)	(13.88)	(196.71)	(5.05)	(1.78)	(35.23)
Earnings before depreciation, amortization, financial cost and income tax expenses	22.82	0.57	(22.26)	(97.52)	7.68	(7.12)	(92.64)
Basic earnings per share (Baht)	0.03	(0.03)	(0.06)	(196.71)	(0.02)	(0.01)	(35.23)
Gross profit margin (%)	41.32	33.80		(7.52)	35.49		(1.69)
Earnings before depreciation, amortization, financial cost and income tax expenses margin (%)	25.46	0.97		(24.49)	11.43		(10.46)
Net profit (loss) margin (%)	9.45	(9.53)		(18.97)	(6.49)		(3.03)
Net profit (loss) margin (holders of the Company) (%)	7.87	(11.70)		(19.57)	(7.51)		(4.19)

Consolidated Statement of Profit or Loss — for the Six-Month Period

Unit : Million Baht	Six-Month 2025	Six-Month 2026	YoY (Baht)	YoY (%)
Revenue from services	180.11	125.54	(54.57)	(30.30)
Cost of services	106.27	81.97	(24.30)	(22.86)
Gross profit	73.85	43.57	(30.28)	(41.00)
Other income	0.86	0.15	(0.71)	(82.38)
Distribution costs	13.35	12.94	(0.41)	(3.09)
Administrative expenses	41.97	42.10	0.12	0.29
Profit (loss) from operating activities	19.39	(11.31)	(30.69)	(158.34)
Financial cost	1.05	0.97	(0.08)	(7.79)
Reversal of expected credit losses	-	0.01	0.01	100.00
Profit (loss) before income tax expenses	18.33	(12.27)	(30.60)	(166.94)
Income tax expenses	2.93	(2.35)	(5.28)	(180.26)
Net profit (loss) for the year	15.40	(9.92)	(25.33)	(164.40)
Attributable to Parent Company	12.80	(11.87)	(24.67)	(192.73)
Earnings before depreciation, amortization, financial cost and income tax expenses	43.67	8.25	(35.42)	(81.11)
Basic earnings per share (Baht)	0.06	(0.05)	(0.11)	(192.73)
Gross profit margin (%)	41.00	34.71		(6.29)
Earnings before depreciation, amortization, financial cost and income tax expenses margin (%)	24.25	6.57		(17.68)
Net profit (loss) margin (%)	8.55	(7.90)		(16.46)
Net profit (loss) margin (holders of the Company) (%)	7.11	(9.46)		(16.56)

Quarterly Operating Performance Analysis

Quarterly Revenue Structure

Revenue structure (Unit : Million Baht)	Q2		Q1		Q2		% Increase (Decrease)	
	2025	%	2026	%	2026	%	QoQ	YoY
Revenue from Intracytoplasmic Sperm Injection ICSI ⁽¹⁾	62.92	69.54	43.72	65.04	37.42	63.99	(14.43)	(40.53)
Revenue from Preimplantation Genetic Testing for Anueploities (PGT-A)	12.05	13.32	9.36	13.92	6.79	11.61	(27.45)	(43.66)
Revenue from preliminary examination before counselling or treatment ⁽²⁾	11.63	12.85	10.73	15.96	10.16	17.38	(5.27)	(12.58)
Revenue from Oocyte Freezing Service	2.39	2.64	2.89	4.29	3.38	5.78	17.10	41.64
Revenue from Intra-Uterine Insemination IUI	0.67	0.74	0.51	0.75	0.59	1.00	15.68	(12.27)
Total revenue from service	89.65	99.08	67.21	99.97	58.33	99.78	(13.20)	(34.93)
Others income	0.83	0.92	0.02	0.03	0.13	0.22	563.02	(84.18)
Total Revenue	90.48	100.00	67.23	100.00	58.47	100.00	(13.03)	(35.38)

Remark: (1) Revenue from ICSI service and other services, including Testicular Sperm Extraction (TESE), Eggs/Sperm/Embryo Freezing, Endometrial Receptivity Analysis (ERA TEST), and Blastocyst culture (Closed system) through Geri plus.

(2) Revenue from preliminary examination before counseling or treatment includes consultation fee, laboratory examination fee, and Ultrasound and Endoscopy fee. (3) Other revenue includes interest revenue.

Six-Month Revenue Structure

Revenue structure (Unit : Million Baht)	Six-Month 2025		Six-Month 2026		Increase (Decrease)	
	2025	%	2026	%	Baht	%
Revenue from Intracytoplasmic Sperm Injection ICSI ⁽¹⁾	126.21	69.74	81.14	64.55	(45.07)	(35.71)
Revenue from Preimplantation Genetic Testing for Anueploities (PGT-A)	25.88	14.30	16.15	12.85	(9.73)	(37.61)
Revenue from preliminary examination before counselling or treatment ⁽²⁾	22.12	12.22	20.89	16.62	(1.22)	(5.53)
Revenue from Oocyte Freezing Service	4.59	2.54	6.27	4.98	1.68	36.53
Revenue from Intra-Uterine Insemination IUI	1.31	0.73	1.09	0.87	(0.22)	(16.75)
Total revenue from service	180.11	99.53	125.54	99.88	(54.57)	(30.30)
Others income	0.86	0.47	0.15	0.12	(0.71)	(82.38)
Total Revenue	180.97	100.00	125.69	100.00	(55.28)	(30.55)

Remark: (1) Revenue from ICSI service and other services, including Testicular Sperm Extraction (TESE), Eggs/Sperm/Embryo Freezing, Endometrial Receptivity Analysis (ERA TEST), and Blastocyst culture (Closed system) through Geri plus.

(2) Revenue from preliminary examination before counseling or treatment includes consultation fee, laboratory examination fee, and Ultrasound and Endoscopy fee. (3) Other revenue includes interest revenue.


Revenue from Services

In Q2/2026, the Company recorded revenue from services of Baht 58.33 million, a decrease of Baht 31.31 million or 34.93 percent compared with Q2/2025 (Baht 89.65 million), and a decrease of Baht 8.87 million or 13.20 percent compared with Q1/2026 (Baht 67.21 million). The decline was driven by a lower number of infertility patients receiving treatment, consistent with the number of treatment cycles in Q2/2026, which decreased by 89 cycles or 41.20 percent compared with Q2/2025 (216 cycles), and decreased by 12 cycles or 8.63 percent compared with Q1/2026 (139 cycles). The decline in service revenue was smaller than the decline in treatment cycles on a year-on-year basis because it was offset by the adjustment of treatment package pricing, with the average price increasing from Baht 0.42 million per treatment cycle in 2025 to Baht 0.46 million per cycle in Q2/2026, representing a price increase of 10.67 percent. Compared with Q1/2026, however, service revenue declined at a faster rate than treatment cycles, as the average treatment

program price decreased from Baht 0.48 million to Baht 0.46 million per treatment cycle, or approximately 5 percent.

For the six-month period of 2026, the Company recorded revenue from services of Baht 125.54 million, a decrease of Baht 54.57 million or 30.30 percent compared with the same period of 2025 (Baht 180.11 million), driven by a lower number of infertility patients receiving treatment, consistent with the number of treatment cycles for the first half of 2026, which decreased by 166 cycles or 38.43 percent compared with the six-month period of 2025. Revenue from services declined by only 30.30 percent, as the decline was partially offset by the adjustment of treatment package pricing from Baht 0.42 million to Baht 0.46 million per treatment cycle, representing a price increase of 13.20 percent, as shown in the chart below.

Number of treatment cycles from 2023 to Q2/2026 is as follows:



Cost of Services

In Q2/2026, the Company recorded cost of services of Baht 38.62 million, a decrease of Baht 13.99 million or 26.59 percent compared with Q2/2025 (Baht 52.60 million), driven by:

- Medicine and medical supplies costs decreased by Baht 5.87 million, in line with lower revenue from services.
- Professional fees of physicians and medical technicians decreased by Baht 4.29 million, in line with lower revenue from services.
- Depreciation of buildings, building improvements and medical equipment decreased by Baht 3.49 million, following the Group's change in the estimated useful lives of assets.

Cost of services also decreased by Baht 4.73 million, or 10.92 percent, compared with Q1/2026 (Baht 43.35 million), driven by lower medicine and medical supplies costs and lower professional fees of physicians and medical technicians, both of which moved in line with the decrease in revenue from services.

For the six-month period of 2026, the Company recorded cost of services of Baht 81.97 million, a decrease of Baht 24.30 million or 22.86 percent compared with the six-month period of 2025 (Baht 106.27 million), primarily driven by:

- Medicine and medical supplies costs decreased by Baht 12.75 million, in line with lower revenue from services.
- Professional fees of physicians and medical technicians decreased by Baht 7.92 million, in line with lower revenue from services.

Gross Profit and Gross Profit Margin

In Q2/2026, the Company recorded gross profit of Baht 19.72 million, a decrease of Baht 17.33 million or 46.77 percent compared with Q2/2025 (Baht 37.04 million), and a decrease of Baht 4.14 million or 17.34 percent compared with Q1/2026 (Baht 23.86 million), driven by lower medicine and medical supplies costs and lower professional fees of physicians and medical technicians in line with the decrease in revenue from services, as discussed under Cost of Services.

Gross profit margin in Q2/2026 stood at 33.80 percent, a decrease of 7.52 percentage points compared with Q2/2025, and a decrease of 1.69 percentage points compared with Q1/2026 (35.49 percent), as revenue from services declined substantially to a level at which fixed costs — such as depreciation and employee expenses — could not be fully absorbed.

For the six-month period of 2026, the Company recorded gross profit of Baht 43.57 million, a decrease of Baht 30.28 million or 41 percent compared with the six-month period of 2025 (Baht 73.85 million), while the gross profit margin for the six-month period of 2026 stood at 34.71 percent, a decrease of 6.29 percentage points compared with the same period of 2025 (41 percent), for the reasons discussed above.

Other Income

In Q2/2026, the Company recorded other income of Baht 0.13 million, a decrease of Baht 0.70 million or 84.18 percent compared with Q2/2025 (Baht 0.83 million), as Q2/2025 included the reversal of advance receipts and prepaid expenses recognized as income of Baht 0.56 million, together with lower interest income. Other income increased by Baht 0.11 million, or 563.02 percent, compared with Q1/2026, from interest income arising in Q2/2026.

For the six-month period of 2026, the Company recorded other income of Baht 0.15 million, a decrease of Baht 0.71 million or 82.38 percent compared with the six-month period of 2025 (Baht 0.86 million), as the prior-year period included the reversal of advance receipts and prepaid expenses recognized as income of Baht 0.56 million in Q2/2025.

Distribution Costs

In Q2/2026, the Company recorded distribution costs of Baht 7.06 million, an increase of Baht 0.63 million or 9.81 percent compared with Q2/2025 (Baht 6.43 million), primarily driven by an increase in advertising, public relations and sales promotion expenses of Baht 0.92 million, partly offset by a decrease in credit card fees of Baht 0.50 million. Distribution costs increased by Baht 1.19 million, or 20.25 percent, compared with Q1/2026 (Baht 5.87 million), driven by:

- Advertising, public relations and sales promotion expenses increased by Baht 0.85 million, relating to the Company's 9th-anniversary celebration campaign.
- Credit card fees decreased by Baht 0.30 million, in line with lower service receipts following the decline in revenue from services.
- Other expenses increased by Baht 0.39 million from exhibition expenses, and employee expenses increased by Baht 0.25 million from a higher headcount in the marketing function.

For the six-month period of 2026, the Company recorded distribution costs of Baht 12.94 million, a decrease of Baht 0.41 million or 3.09 percent compared with the six-month period of 2025 (Baht 13.35 million) — a modest decline relative to the larger decrease in revenue from services, reflecting the use of advertising and sales promotion budgets to stimulate service demand.

Administrative Expenses

In Q2/2026, the Company recorded administrative expenses of Baht 19.31 million, a decrease of Baht 1.54 million or 7.39 percent compared with Q2/2025 (Baht 20.85 million), primarily driven by:

- Employee expenses increased by Baht 0.92 million, from the annual salary adjustment at the beginning of 2026 together with a higher headcount across departments.

- Depreciation decreased by Baht 1.66 million, following the Group's change in the estimated useful lives of assets.
- Directors' remuneration decreased by Baht 0.33 million, and other service fees decreased by Baht 0.46 million.

Administrative expenses decreased by Baht 2.35 million, or 10.85 percent, compared with Q1/2026 (Baht 21.66 million), primarily driven by:

- Employee expenses decreased by Baht 0.79 million, as Q1/2026 included the severance payment made to employees.
- Depreciation decreased by Baht 1.72 million, following the Group's change in the estimated useful lives of assets.
- Professional fees decreased by Baht 0.39 million, relating to legal professional fees in respect of the litigation brought against the Company by employees.

For the six-month period of 2026, the Company recorded administrative expenses of Baht 42.10 million, an increase of Baht 0.12 million or 0.29 percent compared with the six-month period of 2025 (Baht 41.97 million). Administrative expenses for the six-month period of 2026 include the loss from the write-off of assets arising from an exchange-of-services contract, for which the Company did not receive the services in exchange, of Baht 1.12 million. Excluding this item, administrative expenses decreased by a total of Baht 1.00 million, primarily attributable to the following:

- Employee expenses increased by Baht 2.92 million, comprising severance payments to employees of Baht 0.90 million, the annual salary adjustment, and a higher headcount.
- Depreciation decreased by Baht 1.43 million, following the Group's change in the estimated useful lives of assets.
- Directors' remuneration decreased by Baht 0.81 million, reflecting a reduction of two directors in 2026.
- Other expenses decreased by Baht 1.54 million, relating to the Grand Opening event expenses of the Rama 9 International branch incurred in the prior-year period.

Financial Cost

Financial cost consists entirely of interest on long-term lease liabilities of the Group, the majority of which relate to GFC Ubon Co., Ltd.

Expected Credit Losses

In Q1/2026, the Company recognized expected credit losses of Baht 1.12 million, arising from an allowance for contract assets that were not expected to be recovered as consideration in exchange for services rendered. In Q2/2026, the Company wrote off the contract assets in full against the allowance previously recognized, with the loss from the write-off presented within administrative expenses, as discussed under Administrative Expenses.

Earnings before Depreciation, Amortization, Financial Cost and Income Tax Expenses (EBITDA)

In Q2/2026, the Company recorded EBITDA of Baht 0.57 million, a decrease of Baht 22.26 million or 97.52 percent compared with Q2/2025 (Baht 22.82 million), and a decrease of Baht 7.12 million or 92.64 percent compared with Q1/2026 (Baht 7.68 million). The EBITDA margin in Q2/2026 was 0.97 percent, a decrease of 24.49 percentage points compared with Q2/2025 (25.46 percent) and a decrease of 10.46 percentage points compared with Q1/2026 (11.43 percent). The decline arose from three key factors: (1) lower revenue from services in line with the number of treatment cycles; (2) the largely fixed nature of cash costs and expenses — particularly employee-related expenses and utilities — which cannot be scaled down as quickly as the decline in revenue; and (3) higher distribution costs from the acceleration of marketing activities to support the second-half revenue plan.

For the six-month period of 2026, the Company recorded EBITDA of Baht 8.25 million, a decrease of Baht 35.42 million or 81.11 percent compared with the six-month period of 2025 (Baht 43.67 million), while the EBITDA margin for the six-month period of 2026 stood at 6.57 percent, a decrease of 17.68 percentage points compared with the same period of 2025 (24.25 percent), for the reasons discussed in the preceding paragraph.

Net Profit (Loss) and Net Profit Margin

In Q2/2026, the Company recorded a net loss of Baht 5.56 million, a decrease of Baht 14.03 million or 165.64 percent compared with Q2/2025 (net profit of Baht 8.47 million), and a decrease of Baht 1.19 million or 27.37 percent compared with Q1/2026 (net loss of Baht 4.36 million). The net loss margin in Q2/2026 was 9.53 percent, a decrease of 18.97 percentage points compared with Q2/2025 (net profit margin of 9.45 percent) and a decrease of 3.03 percentage points compared with Q1/2026 (net loss margin of 6.49 percent).

Financial Position Analysis

Assets

As of June 30, 2026, the Company had total assets of Baht 620.76 million, a decrease of Baht 50.57 million or 7.53 percent compared with December 31, 2025, with details as follows:

As at (Unit : Million Baht)	December 31, 2025	June 30, 2026	Change	
			Amount	%
Current assets				
Cash and cash equivalents	130.75	98.28	(32.47)	(24.84)
Trade and other current receivable	4.35	4.26	(0.08)	(1.87)
Contract assets – current	1.97	1.44	(0.53)	(26.84)
Inventories	21.14	17.19	(3.95)	(18.68)
Current tax assets	0.23	0.21	(0.03)	(11.10)
Total current assets	158.43	121.37	(37.06)	(23.39)
Non-current assets				
Bank deposit used as collateral	1.04	1.04	-	-
Property, plant and equipment	481.50	467.45	(14.05)	(2.92)
Right-of-use assets	23.26	19.90	(3.36)	(14.46)
Intangible assets	2.78	2.91	0.12	4.43
Deferred tax assets	1.78	5.33	3.56	200.42
Other non-current assets	2.56	2.77	0.21	8.39
Total non-current assets	512.91	499.39	(13.52)	(2.64)
Total assets	671.34	620.76	(50.57)	(7.53)

Current Assets

As of June 30, 2026, current assets stood at Baht 121.37 million, a decrease of Baht 37.06 million or 23.39 percent compared with December 31, 2025, primarily driven by:

- Cash and cash equivalents decreased by Baht 32.47 million, comprising net cash used in investing activities of Baht 3.71 million (mainly payments to creditors for the purchase of assets) and net cash used in financing activities of Baht 31.08 million from payment of lease liabilities and dividend payments to shareholders, partly offset by net cash provided by operating activities of Baht 2.32 million.

**Non-current Assets**

As of June 30, 2026, non-current assets stood at Baht 499.39 million, a decrease of Baht 13.52 million or 2.64 percent compared with December 31, 2025, primarily driven by:

- Property, plant and equipment decreased by Baht 14.05 million, from depreciation for the period net of asset acquisitions.
- Right-of-use assets decreased by Baht 3.36 million, from amortization for the period.
- Deferred tax assets increased by Baht 3.56 million, from the tax loss recognized during the period.

Liabilities

As of June 30, 2026, the Company had total liabilities of Baht 66.02 million, a decrease of Baht 15.65 million or 19.17 percent compared with December 31, 2025, with details as follows:

As at (Unit : Million Baht)	December 31, 2025	June 30, 2026	Change	
			Million Baht	%
Current liabilities				
Trade and other current payables	35.51	23.13	(12.39)	(34.88)
Contract liabilities	9.09	10.46	1.36	15.00
Current portion of lease liabilities	10.83	9.27	(1.56)	(14.42)
Corporate income tax payable	1.77	1.19	(0.58)	(32.96)
Total current liabilities	57.21	44.04	(13.17)	(23.02)
Non-current liabilities				
Lease liabilities	19.25	15.62	(3.63)	(18.86)
Provision for employee benefit	5.21	6.35	1.15	22.00
Total non-current liabilities	24.46	21.97	(2.49)	(10.16)
Total liabilities	81.67	66.02	(15.65)	(19.17)

Current Liabilities

As of June 30, 2026, current liabilities stood at Baht 44.04 million, a decrease of Baht 13.17 million or 23.02 percent compared with December 31, 2025, primarily driven by:

- Trade and other current payables decreased by Baht 12.39 million, from payments of construction-related and asset-purchase payables, trade payables, and employee bonuses.
- Contract liabilities increased by Baht 1.36 million, from advance receipts for treatment packages and chromosomal screening services.
- The current portion of lease liabilities decreased by Baht 1.56 million, from payments of lease liabilities.

Non-current Liabilities

As of June 30, 2026, non-current liabilities stood at Baht 21.97 million, a decrease of Baht 2.49 million or 10.16 percent compared with December 31, 2025, primarily driven by:

- Lease liabilities decreased by Baht 3.63 million, from payments of lease liabilities during the period.

Shareholders' Equity

As at (Unit : Million Baht)	December 31, 2025	June 30, 2026	Change	
			Million Baht	%
Issued and paid-up share capital	110.00	110.00	-	-
Share premium on ordinary shares	372.79	372.79	-	-
Legal reserve	11.00	11.00	-	-

Unappropriated retained earnings	73.89	40.02	(33.87)	(45.84)
Non-controlling interests	21.99	20.94	(1.05)	(4.77)
Total shareholder's equity	589.67	554.75	(34.92)	(5.92)

As of June 30, 2026, shareholders' equity stood at Baht 554.75 million, a decrease of Baht 34.92 million or 5.92 percent, driven by the net loss for the period attributable to the parent company of Baht 11.87 million, the dividend payment of Baht 22.00 million, and the dividend paid to the non-controlling shareholders of a subsidiary of Baht 3.00 million, net of the profit attributable to non-controlling interests of Baht 1.95 million.

Cash Flow

For the six-month period of 2026, the Company recorded a net decrease in cash of Baht 32.47 million. Cash and cash equivalents at the beginning of the period stood at Baht 130.75 million, resulting in cash and cash equivalents as of June 30, 2026 of Baht 98.28 million. The breakdown of cash flow by activity is as follows:

For the period (Unit : Million Baht)	June 30, 2025	June 30, 2026
Net cash provided by operating activities	24.65	2.32
Net cash used in investing activities	(37.19)	(3.71)
Net cash used in financing activities	(37.58)	(31.08)
Net decrease in cash and cash equivalent	(50.13)	(32.47)
Cash and cash equivalent at the beginning period	158.31	130.75
Cash and cash equivalent at the end of period	108.18	98.28

Cash Flow from Operating Activities

The Company reported operating profit before changes in operating assets and liabilities of Baht 11.34 million and cash generated from operating activities of Baht 4.20 million, with income tax payments of Baht 2.00 million and interest received of Baht 0.12 million during the period. As a result, net cash provided by operating activities for the six-month period ended June 30, 2026 amounted to Baht 2.32 million.

Cash Flow from Investing Activities

For the six-month period ended June 30, 2026, net cash used in investing activities amounted to Baht 3.71 million, mainly comprising payments to creditors for the purchase of assets.

Cash Flow from Financing Activities

For the six-month period ended June 30, 2026, net cash used in financing activities amounted to Baht 31.08 million, comprising dividend payments to shareholders and payments of lease liabilities.

Key Financial Ratios

Liquidity Ratios

Ratios	Unit	December 31, 2025	June 30, 2026
Current ratio	Times	2.77	2.76
Cash ratio	Times	2.29	2.23
Quick ratio	Times	2.36	2.33
Inventory turnover ratio	Times	10.64	8.12

Average sale period	Days	34.31	44.93
Account receivable turnover ratio	Times	77.42	66.66
Average collection period	Days	4.71	5.48
Account payable turnover ratio	Times	3.97	5.64
Average payment period	Days	91.96	64.70
Cash cycle	Days	(52.93)	(14.30)

As of June 30, 2026, the Company had a current ratio of 2.76 times, a marginal decrease of 0.01 times compared with December 31, 2025.

Profitability Ratios

Ratios	Unit	June 30, 2025	March 31, 2026	June 30, 2026
Gross profit margin	%	41.32	35.49	33.80
EBITDA margin	%	25.46	11.43	0.97
EBIT margin	%	11.82	(5.44)	(11.18)
NPAT margin	%	9.45	(6.49)	(9.53)
Return on Equity *	%	7.02	2.02	(0.41)

* Trailing 12 months

The Company's EBITDA margin, EBIT margin and net profit margin (NPAT) for Q2/2026 were 0.97 percent, (11.18) percent and (9.53) percent, respectively — a decrease of 24.49, 23.00 and 18.97 percentage points, respectively, compared with Q2/2025. This was driven by the decrease in revenue from services and the cost of services structure, as discussed in the Operating Performance Analysis section.

Operating Efficiency Ratios

Ratios	Unit	December 31, 2025	June 30, 2026
Return on assets *	%	4.98	0.80
Return on fixed assets *	%	6.87	1.03

* Trailing 12 months

As of June 30, 2026, return on assets and return on fixed assets stood at 0.80 percent and 1.03 percent, respectively, both decreasing compared with December 31, 2025, due to lower profit from operating activities.

Financial Policy Analysis Ratios

Ratios	Unit	December 31, 2025	June 30, 2026
Debt-to-equity ratio	Times	0.14	0.12
Dividend payout ratio	%	269.70	-

As of June 30, 2026, the debt-to-equity ratio stood at 0.12 times, a slight decrease compared with December 31, 2025 (0.14 times).

The dividend payout ratio for the year 2025 stood at 269.70 percent. No dividend payout ratio is presented for the six-month period of 2026, as the Company recorded a net loss for the period; the interim dividend was paid from the Company's retained earnings.

Dividend Payment to Shareholders

The Board of Directors' Meeting No. 4/2026, held on August 10, 2026, approved the payment of an interim dividend from the Company's retained earnings to shareholders at the rate of Baht 0.03 per share, totaling Baht 6.60 million, with the dividend payment scheduled by September 8, 2026.